Literature DB >> 23534348

Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy.

Yo-Ichi Yamashita1, Ken Shirabe, Takeo Toshima, Eiji Tsuijita, Kazuki Takeishi, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Tetsuo Ikeda, Yuji Soejima, Yoshihiko Maehara.   

Abstract

AIM: Hepatitis C (HC)-related hepatocellular carcinoma (HCC; HC-HCC) is highly recurrent.
METHODS: From 1995-2007, 183 curative hepatic resections for primary solitary HC-HCC without postoperative interferon therapy were included in this study. The patients were divided into three groups: (i) 2 cm or less (n = 56); (ii) more than 2 cm to less than 5 cm (n = 79); and (iii) 5 cm or more (n = 48). Independent risk factors for HC-HCC recurrence for each group were determined.
RESULTS: Independent risk factors for recurrence were aspartate aminotransferase or alanine aminotransferase (AST/ALT) of 80 IU/L or more (hazard ratio [HR], 2.1; P = 0.02) in patients with HCC of 2 cm or less, des-γ-carboxy prothrombin of 100 mAU/mL or more (HR, 2.5; P = 0.02) and AST/ALT of 80 IU/L or more (HR, 2.1; P = 0.04) in patients with HCC of more than 2 cm to less than 5 cm, and the presence of macroscopic portal vein tumor thrombus (HR, 2.8; P = 0.02) and AST/ALT of 80 IU/L or more (HR, 2.1; P = 0.04) in patients with HCC of 5 cm or more. All 13 late recurrences of 1 year or more after hepatic resection (27.1%) in patients with HCC of 5 cm or more were accompanied by AST/ALT of 80 IU/L or more.
CONCLUSION: AST/ALT of 80 IU/L or more is an independent risk factor for the recurrence of primary solitary HC-HCC after curative resection irrespective of the primary HC-HCC size.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  hepatitis C virus; hepatocellular carcinoma; risk factors; tumor recurrence

Year:  2013        PMID: 23534348     DOI: 10.1111/hepr.12091

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  2 in total

Review 1.  Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.

Authors:  Jian-Hong Zhong; Qing-Lian Zhong; Le-Qun Li; Hang Li
Journal:  Tumour Biol       Date:  2014-08-14

2.  Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection.

Authors:  Junfei Jin; Pengpeng Zhu; Yan Liao; Jun Li; Weijia Liao; Songqing He
Journal:  Oncotarget       Date:  2015-08-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.